Table 1 Clinicopathological features of 78 patients with Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma
Factors | Median (range or proportion) |
|---|---|
Sex (male/female) | 66:12 (84.6 %:15.4 %) |
Age (years) | 56.0 (33–80) |
Alcohol consumption (no/yes)a | 56:20 (73.7:26.3) |
Preoperative TACE (no/yes) | 67:11 (85.9 %:14.1 %) |
HBsAg (negative/positive) | 7:71 (9.0 %:91.0 %) |
Anti-HCV (negative/positive) | 76:2 (97.4 %:2.6 %) |
ALT (U/L) | 45.5 (12–191) |
GGT (U/L) | 49.5 (15–395) |
Child–Pugh Classification (A/B) | 76:2 (97.4 %:2.6 %) |
Cirrhosis (no/yes) | 5:73 (6.4 %:93.6 %) |
Portal hypertension (no/yes) | 65:13 (83.3 %:16.7 %) |
Liver resection range (hepatic segment) | 2 (1–4) |
Resection margin (mm)a | 5 (0–30) |
Anatomical resection (yes/no) | 18:60 (23.1 %:76.9 %) |
Hepatic inflow occlusion (no/yes) | 33:45 (42.3:57.7) |
Intraoperative blood loss (mL) | 300 (100–3500) |
Blood transfusion (mL) | 0.0 (0–1100) |
Preoperative alpha-fetoprotein (μg/L) | 17.8 (1.1–1211.0) |
Cumulative tumor size (cm) | 5.0 (2.5–20.0) |
Tumor number | 3 N |
Differentiation (high/middle and low/necrosis) | 3:73:2 (3.8 %:93.6 %:2.6 %) |
Liver capsule invasion (no/yes) | 12:66 (15.4 %:84.6 %) |